KOBO BIOTECH LIMITED is a Chemicals & Petrochemicals company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY20 | FY21 | FY22 | FY23 | FY24 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| EBITDA (ex other income) | (1) | (3) | (11) | (1) | (1) |
| margin % | — | — | — | — | — |
| Owners' profit | (21) | (19) | (15) | (6) | (5) |
| EPS, as reported (₹) | (8.82) | (8.07) | (6.39) | (2.33) | (2.33) |
| ROE % · ROCE % | 23.9 · 13.6 | 17.9 · 12.2 | 12.4 · 17.9 | 4.3 · 6.1 | 3.7 · 5.1 |
| Debt / equity (x) | (2.26) | (1.94) | (1.15) | (1.09) | (1.05) |
| Cash from operations | — | 14 | 94 | 1 | 0 |
| Capex | — | 0 | 0 | 0 | 0 |
| ₹ crore | Q2 FY23 | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | (1) | (1) | (2) | (1) | (1) | (1) | (1) | (1) |
| Net profit | (1) | (1) | (2) | (1) | (1) | (1) | (1) | (1) |
| EPS (₹) | (0.46) | (0.50) | (0.75) | 0.00 | 0.00 | (0.52) | (0.53) | 0.00 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DEEPAK FERTILIZERS & PETR | 16,727 | 17.0 | 2.24 | 12.2 | 9.9 | 8.4 | 14.6 | 26.1 |
| TATA CHEMICALS LTD | 15,683 | — | 0.71 | 141.2 | (7.7) | (5.0) | 7.4 | 14.4 |
| GUJ NAR VAL FER & CHEM L | 8,273 | 8.0 | 0.91 | 6.0 | 8.9 | 10.3 | 8.7 | 22.1 |
| TANFAC INDUSTRIES LTD. | 6,773 | 55.4 | 18.15 | — | 18.8 | 24.3 | — | 16.0 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 24 Jul 2026 · 32nd AGM held via video conferencing; annual accounts adopted with 100% approval | board shareholder meetings | low | — | — |
| 24 Jul 2026 · 32nd AGM held via VC; one resolution passed with 100% assent | board shareholder meetings | low | — | — |
| 24 Jul 2026 · Kobo Biotech 31st AGM: FY24 accounts adopted; only 0.08% voting turnout | compliance | minimal | — | — |
| 24 Jul 2026 · Kobo Biotech 31st AGM adopts FY24 accounts with 100 percent assent | board shareholder meetings | low | — | — |
| 17 Jul 2026 · RTA compliance certificate filed for June 2026 quarter | compliance | minimal | — | — |
| 16 Jul 2026 · Resolution Plan implementation delayed; Monitoring Committee meeting called | regulatory legal | high | — | — |
| 29 Jun 2026 · Annual Report FY25 filed during CIRP, zero revenue, resolution plan approved | results | high | — | — |
| 29 Jun 2026 · Annual Report for Financial Year 2023-24 filed with BSE | results | high | — | — |
| 26 Jun 2026 · Notice and Annual Report for 2025 AGM shared by Kobo Biotech | board shareholder meetings | low | — | — |
| 26 Jun 2026 · Kobo Biotech 31st AGM notice on July 24, 2026 via video conferencing | board shareholder meetings | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| GUJARAT ALKALIES & CHEM | 5,179 | 78.0 | 1.00 | 10.7 | (0.0) | 0.7 | 12.4 | 18.4 |
| GHCL LIMITED | 3,879 | 8.4 | 1.09 | 5.1 | 13.3 | 16.6 | 1.1 | 23.9 |
| GRAUER & WEIL IND LTD | 3,469 | 21.2 | 3.21 | 14.1 | 15.2 | 19.2 | 14.5 | 20.4 |
| J.G.CHEMICALS LIMITED | 2,330 | 31.0 | 4.31 | 23.7 | 12.7 | 16.9 | — | 11.5 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| ROCE | 5.1 | 6.2 | 36 of 65 | 45% |
| ROE | 3.7 | 4.9 | 37 of 65 | 44% |
| Debt / Equity | (1.1) | 0.2 | 2 of 65 | 98% |
| Profit growth | (8.5) | 21.0 | 42 of 64 | 35% |
| Market cap | 11 | 77 | 58 of 65 | 11% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
